. Author manuscript; available in PMC: 2021 Jul 12.

Published in final edited form as: Clin Cancer Res. 2021 Jan 20;27(7):1882–1892. doi: 10.1158/1078-0432.CCR-20-3946

Table 4. Grade 3 and higher adverse events for all cycles in the dose expansion phase.

Characteristic	GC + guadecitabine	GC	Total
n	10	10	20
Patients that experienced at least one AE graded 3 or above	8 (80.0%)	7 (70.0%)	15 (75.0%)
Blood and lymphatic system disorders
Febrile neutropenia	1 (10.0%)	0 (0.0%)	1 (5.0%)
Neutropenia	4 (40.0%)	5 (50.0%)	9 (45.0%)
Leukopenia	1 (10.0%)	0 (0.0%)	1 (5.0%)
Thrombocytopenia	4 (40.0%)	3 (30.0%)	7 (35.0%)

General disorders
Pyrexia	1 (10.0%)	1 (10.0%)	2 (10.0%)

Infections and infestations
Urinary tract infection	1 (10.0%)	1 (10.0%)	2 (10.0%)

Respiratory, thoracic and mediastinal disorders
Pulmonary embolism	1 (10.0%)	1 (10.0%)	2 (10.0%)

Skin and subcutaneous tissue disorders
Rash	1 (10.0%)	1 (10.0%)	2 (10.0%)

GC, gemcitabine and guadecitabine; AE, adverse event